A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336

被引:1
|
作者
Carroll, F. Ivy [1 ]
Kosten, Thomas R. [2 ]
Buda, Jeffrey J. [1 ]
Wang, Laurene [3 ]
Walters, Bradford B. [1 ]
机构
[1] RTI Int, Res Triangle Pk, NC 27709 USA
[2] Baylor Coll Med, Psychiat Neurosci Pharmacol & Immunol & Pathol, Houston, TX 77030 USA
[3] INDApharma, Chapel Hill, NC USA
来源
关键词
RTI-336; dopamine transporter inhibitor; Clinical Trials; cocaine dependence; addiction and addiction behaviors; pharmacokinetics and drug metabolism (PDM); safety; tolerability; COCAINE USE DISORDER; DOPAMINE TRANSPORTER; NONHUMAN-PRIMATES; SQUIRREL-MONKEYS; RHESUS-MONKEYS; ABUSE; ANALOGS; DRUGS; PHARMACOTHERAPY; INHIBITORS;
D O I
10.3389/fphar.2018.00712
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Preclinical and clinical data suggest that a compound which binds potently to and inhibits the dopamine transporter, but with a slower onset and offset rate than cocaine and with less abuse potential and psychomotor stimulant activity, could be a useful adjunct in the treatment of cocaine dependence. Methods: We assessed the safety, tolerability, and pharmacokinetics (PK) of oral single doses (0.3, 1, 3, 6, 12, and 20 mg) of such an analog, RTI-336, in a randomized, double-blind, and placebo-controlled trial in healthy adult males. Pre-dose and post-dose safety assessments included physical examinations (including neurological examination); orthostatic vital signs; 6-lead continuous electrocardiogram (ECG) telemetry monitoring pre-dose to 8 h post-dose; 12-lead ECGs; clinical chemistry, hematology, and urinalysis; mini mental status examinations; and adverse events. RTI-336 PK was assessed in plasma and urine. Results: 22 participants were enrolled. RTI-336 was well-tolerated up to the maximum evaluated dose of 20 mg. PK analyses demonstrated good absorption with peak plasma maximum concentrations (C-max) occurring around 4 h post-dose and consistent half-lives of around 17 h for the 6, 12, and 20 mg doses. Plasma drug exposure and Cmax increased in proportion to dose. Only 0.02% of RTI-336 excreted was unchanged in urine. Active metabolites UC-M5, UC-M8, and UC-M2 were measurable in plasma and urine, with plasma Cmax of UC-M5 and UC-M8 exceeding that of RTI-336. Three AE possibly were related to RTI-336 and resolved with discontinuation; the one serious AE was unrelated to RTI-336. 2 participants had transient and mild serum total bilirubin elevations (< 1.5 x upper limit of normal) at day 3 post-dose which resolved by day 8 post-dose. Conclusion: All doses including the highest (20 mg) showed excellent safety and tolerability, and further studies in humans are warranted.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Double-blind, randomized, placebo-controlled evaluation of the safety, tolerability, and pharmacokinetics of CGP 77116 in patients with multiple sclerosis
    Lindsey, JW
    Lublin, FD
    Stark, SR
    Antel, JP
    Oger, JJ
    Erwin, RM
    Evans, AC
    NEUROLOGY, 1998, 50 (04) : A149 - A149
  • [32] Safety, Tolerability, and Pharmacokinetics of NIM-1324 an Oral LANCL2 Agonist in a Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial
    Leber, Andrew
    Hontecillas, Raquel
    Tubau-Juni, Nuria
    Bassaganya-Riera, Josep
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2025, 18 (01):
  • [33] The cult of the double-blind placebo-controlled trial
    Ellis, SJ
    Adams, RF
    BRITISH JOURNAL OF CLINICAL PRACTICE, 1997, 51 (01): : 36 - 39
  • [34] Double-blind, placebo-controlled trial of two doses of abecarnil for geriatric anxiety
    Small, GW
    Bystritsky, A
    JOURNAL OF CLINICAL PSYCHIATRY, 1997, 58 : 24 - 29
  • [35] Safety and Pharmacokinetics of Lisdexamfetamine Dimesylate in Adults With Clinically Stable Schizophrenia A Randomized, Double-Blind, Placebo-Controlled Trial of Ascending Multiple Doses
    Martin, Patrick
    Dirks, Bryan
    Gertsik, Lev
    Walling, David
    Stevenson, Annette
    Corcoran, Mary
    Raychaudhuri, Aparna
    Ermer, James
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2014, 34 (06) : 682 - 689
  • [36] Human Safety and Pharmacokinetics Study of Orally Administered Icariin: Randomized, Double-Blind, Placebo-Controlled Trial
    Brown, E. Sherwood
    Bice, Collette
    Putnam, William C.
    Leff, Richard
    Kulikova, Alexandra
    Nakamura, Alyson
    Ivleva, Elena I.
    Enkevort, Erin Van
    Holmes, Traci
    Miingi, Nyokabi
    NATURAL PRODUCT COMMUNICATIONS, 2019, 14 (06)
  • [37] Tolerability, safety, and pharmacokinetics of GR1603 injection in healthy subjects: a randomized, double-blind, placebo-controlled single-dose escalation clinical trial
    Huang, Xin
    Hong, Xiang
    Yang, Shuang
    Ye, Ling
    Yang, Xiaoyan
    Cui, Chang
    Wu, Qian
    Wang, Wei
    Huang, Jie
    Yang, Guoping
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2025, 34 (1-2) : 89 - 95
  • [38] A double-blind placebo-controlled study of the effectiveness and tolerability of oral stevioside in human hypertension
    Chan, P
    Tomlinson, B
    Chen, YJ
    Liu, JC
    Hsieh, MH
    Cheng, JT
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 50 (03) : 215 - 220
  • [39] A Phase I, Randomized, Double Blind, Placebo-Controlled, Dose Escalating Study of the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Hmpl-523 in Australian Male Healthy Subjects
    Lickliter, Jason
    Wu, Yan
    Hua, Ye
    Yuan, Irena
    Dai, Guangxiu
    Li, Xiong
    Wang, Jian
    Sai, Yang
    Sun, Zhongcui
    Pan, Angela
    Li, Jing
    Su, Weiguo
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [40] A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Tolerability of Prucalopride Oral Solution in Constipated Elderly Patients Living in a Nursing Facility
    Camilleri, Michael
    Kerstens, Rene
    Beyens, Greet
    Robinson, Patricia
    Vandeplassche, Lieve
    GASTROENTEROLOGY, 2009, 136 (05) : A46 - A47